Document is current
Any future updates will be listed below
-
Authors
Najibi, Alexander J. https://orcid.org/0000-0001-7761-392X
Lane, Ryan S. https://orcid.org/0000-0002-6788-3560
Sobral, Miguel C.
Bovone, Giovanni
Kang, Shawn
Freedman, Benjamin R.
Gutierrez Estupinan, Joel
Elosegui-Artola, Alberto
Tringides, Christina M.
Dellacherie, Maxence O.
Williams, Katherine https://orcid.org/0000-0001-8061-0105
Ijaz, Hamza
Müller, Sören https://orcid.org/0000-0001-9490-5270
Turley, Shannon J. https://orcid.org/0000-0002-0444-3031
Mooney, David J. https://orcid.org/0000-0001-6299-1194
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54 CA244726)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA223255)
National Science Foundation
- License Information
-
More Information
Article History
Received: 27 January 2023
Accepted: 30 March 2024
First Online: 6 May 2024
Competing interests
: D.J.M. declares the following competing interests: Novartis, sponsored research, licensed IP; Immulus, equity; IVIVA, SAB; Attivare, SAB, equity; Lyell, licensed IP, equity. R.S.L., K.W., S.M. and S.J.T. are employed by Genentech, Inc. The other authors declare no competing interests.
